Tag: The Lancet
-
Apnimed Publishes Positive Phase 2 Flow Study Results for Sulthiame in Obstructive Sleep Apnea in The Lancet
Overview: Promising Phase 2 Results in The Lancet Apnimed has announced that positive Phase 2 results from the FLOW study evaluating sulthiame, an oral carbonic anhydrase inhibitor, have been published in The Lancet. The publication highlights that sulthiame met the primary endpoint across all tested doses and significantly improved a range of efficacy measures in…
-
Apnimed Announces Lancet Publication: Positive Phase 2 Results for Sulthiame in Obstructive Sleep Apnea
New Lancet Publication Highlights Positive Phase 2 Outcomes Apnimed has revealed breakthrough findings from its Phase 2 FLOW study, showing that sulthiame, an oral carbonic anhydrase inhibitor, met the primary endpoint across all doses tested in obstructive sleep apnea (OSA). The Lancet publication details how sulthiame not only achieved statistical significance on primary measures but…
-
Heart Disease Returns as Global Killer: A Wake-Up Call on Chronic Conditions
Global killer reasserts itself: heart disease, stroke reclaim top spots A new global picture of mortality released in The Lancet highlights a sobering shift: chronic, non-communicable diseases — led by heart disease and stroke — are reclaiming the title of the world’s leading causes of death. COVID-19, once the dominant narrative, has fallen from the…